Pharmacyte Biotech Inc (OTCMKTS:PMCB) inched down a little during the last session, indicating that the hype created around its Diabetes potential is fading away gradually. The stock of the biotechnology company came under the spotlight following a series of positive developments around the company.

Hype built by Goldman Small Cap

Firstly, a research firm, Goldman Small Cap Research, commended the company’s proprietary, Cell-In-A-Box technology. The research report drew points from a recent research paper, which established the fact that Pharmacyte Biotech Inc (OTCMKTS:PMCB)’s technology is an answer to Diabetes.

The research firm’s analyst, Rob Goldman noted in his analytical report that the company has vast potential in $176 billion Diabetes market. The analyst claimed that if the company clears the ongoing trial tests successfully, then it could soon replace the traditional methods of diabetes treatment, which involves insulin injections and medicines.

Is It worthy to replace traditional diabetes treatment?

The report drew conclusions from a recent research paper, which showed that a diabetic mice was cured using Malligen cells that were encapsulated using Pharmacyte Biotech Inc (OTCMKTS:PMCB)’s technology. The paper highlighted on how the company’s technology safeguarded the nature of Malligen cells and rendered them effective while treating diabetes. Undoubtedly, the Goldman Small Cap Research’s report helped the company to receive an unprecedented amount of attention from the investors.

Alongside the research report, Pharmacyte Biotech Inc (OTCMKTS:PMCB) did not miss the chance to reveal that it has appointed Thomas Liquard as Board of Director. An interesting point to note is that Liquard, having being served at Alchemia Ltd and Pfizer Inc holds an extensive experience in the healthcare field, which will benefit the company ultimately.

The stock of Pharmacyte Biotech Inc (OTCMKTS:PMCB) slipped by 6.22% to $0.204 on the last day of the week as 3.52 million shares traded on the day.